Note: Descriptions are shown in the official language in which they were submitted.
NUTRACEUTICAL COMPOSITION FOR PDE4 INHIBITION, ENHANCED
DOPAMINE METABOLISM AND LONG TERM POTENTIATION
BACKGROUND
FIELD OF THE INVENTION
[0002] The invention relates to nutritional supplements and methods of use
thereof.
RELATED ART
[0003] There has been a significant amount of research into the benefits of
PDE4
inhibitors. In animal models synthetic PDE4 inhibitors have been shown to
enhance
object memory, and to reverse deficits to learning, working and reference
memory
induced by scopolamine, NMDA antagonists and under conditions of depleted
tryptophan and serotonin (references 1-6).
[0004] Several articles have been published in the literature that
discuss the
potential of PDE4 inhibitors for cognitive enhancement in those with
Alzheimer's
disease, dementia, and other neurodegenerative conditions. PDE4 inhibitors
have also
provided improvements in performance to aged animal brains and have been
shown,
in animal models, to provide protection from damage from certain types of
ischemic
strokes. Experimental new PDE4 inhibitors are regularly being developed with
the
intention of treating long-term memory loss and mild cognitive impairment.
Unfortunately, one of the most studied PDE4 inhibitors, rolipram, has had the
side
effect of emesis (vomiting) at low doses. Much work remains for developing
memory
enhancing PDE4 inhibitors with better side-effect profiles than rolipram
(references 7-
13).
1
CA 2925318 2020-04-06
CA 02925318 2016-03-23
WO 2015/048590 PCT/US2014/057923
SUMMARY
[0005] In one aspect, a nootropic combination for increasing cognitive
functioning
in a human, or other mammal, is provided. The combination includes effective
amounts of a phosphodiesterase 4 (PDE4) inhibitor and a cyclic adenosine
monophosphate (cAMP) increasing agent. In embodiments of the nootropic
combination: a) the combination includes an effective amount of acetyl-L-
carnitine or
a physiologically acceptable salt thereof; b) the PDE4 inhibitor includes a
flavonoid,
an alkaloid, or a stilbenoid, or any combination thereof; c) the PDE4
inhibitor
includes luteolin, quercetin, hesperidin, biochanin A, genistein,
mesembrenone, or
resveratrol, or a glycoside thereof, a physiologically acceptable salt
thereof, or any
combination thereof; d) the cAMP increasing agent is a labdane diterpene; e)
the
cAMP increasing agent is forskolin, a glycoside thereof, or a physiologically
acceptable salt thereof; f) when the cAMP increasing agent is forskolin, the
forskolin
is in a range of about 0.9 mg to about 4.4 mg per daily dose of the
combination; g)
when the cAMP increasing agent is forskolin, the ratio of acetyl-L-carnitine
to
forskolin is about 200:1 by weight; h) the combination further includes
effective
amounts of one or any combination of components selected from the group
consisting
of L-phenylalanine, L-carnitine, acetyl-L-carnitine, vitamin B6, and a
physiologically
acceptable salt thereof; i) the PDE4 inhibitor, the cAMP increasing agent, or
both,
can be added to the combination in the form of one or more plant extracts; j)
the
combination can be a nutritional supplement; or k) any combination of a) ¨j).
[0006] In another aspect, a nutritional supplement for increasing cognitive
functioning in a human, or other mammal, is provided. The nutritional
supplement
includes effective amounts of forskolin and acetyl-L-carnitine, and further
includes a
plant extract including an effective amount of a PDE4 inhibitor. In
embodiments of
the nutritional supplement: a) the ratio of acetyl-L-carnitine to forskolin is
about
200:1 by weight; b) the forskolin is in a range of about 0.9 mg to about 4.4
mg per
daily dose of the supplement; c) the PDE4 inhibitor includes a flavonoid, an
alkaloid,
or a stilbenoid, or any combination thereof; d) the PDE4 inhibitor includes
luteolin,
quercetin, hesperidin, biochanin A, genistein, mesembrenone, or resveratrol,
or a
2
CA 02925318 2016-03-23
WO 2015/048590 PCT/US2014/057923
glycoside thereof, a physiologically acceptable salt thereof, or any
combination
thereof; e) the forskolin can be added to the nutritional supplement in the
form of a
Coleus forskohlii extract; or f) any combination of a) ¨ e).
[0007] In a further embodiment, a method of increasing cognitive functioning
in a
human or other mammalian subject in need thereof is provided. The method
includes
administering any of the nootropic combinations for increasing cognitive
functioning
described in this application, including any of the nutritional supplements.
Thus, in
some embodiments, the method includes administering to the subject a
nutritional
supplement that includes effective amounts of a cyclic adenosine monophosphate
(cAMP) increasing agent and acetyl-L-carnitine, and further includes a plant
extract
that includes an effective amount of a PDE4 inhibitor. In embodiments of the
method:
a) the cAMP increasing agent is forskolin, a glycoside thereof, or a
physiologically
acceptable salt thereof; b) the PDE4 inhibitor includes a flavonoid, an
alkaloid, or a
stilbenoid, or any combination thereof; c) the PDE4 inhibitor includes
luteolin,
quercetin, hesperidin, biochanin A, genistein, mesembrenone, or resveratrol,
or a
glycoside thereof, a physiologically acceptable salt thereof, or any
combination
thereof; d) the cAMP increasing agent is forskolin; e) when the nootropic
combination includes forskolin, the ratio of acetyl-L-carnitine to forskolin
is about
200:1 by weight; or f) when the nootropic combination includes forskolin, the
forskolin can be added to the nutritional supplement in the form of a Coleus
forskohlii
extract; or g) any combination of a)¨ f).
[0008] In another aspect, a nutritional supplement for increasing cognitive
functioning in a human, or other mammal, is provided. The nutritional
supplement
includes effective amounts of a phosphodiesterase 4 (PDE4) inhibiting
flavonoid and
a cyclic adenosine monophosphate (cAMP) increasing labdane diterpene. In some
embodiments: a) the flavonoid can be luteolin, a glycoside thereof, or a
physiologically acceptable salt thereof; b) the nutritional supplement can
include
artichoke extract as a source of the flavonoid; c) the labdane diterpene can
be
forskolin, a glycoside thereof, or a physiologically acceptable salt thereof;
d) the
nutritional supplement can further include effective amounts of one or any
3
CA 02925318 2016-03-23
WO 2015/048590 PCT/US2014/057923
combination of components selected from the group consisting of L-
phenylalanine, L-
carnitine, acetyl-L-carnitine, vitamin B6, and piperine, and a physiologically
acceptable salt thereof; or e) any combination of a) ¨ d).
[0009] In some embodiments, the nutritional supplement includes in daily
dosage
form about 202.5 mg to about 990 mg of artichoke extract standardized to 5%
cynarin,
and about 0.9 mg to about 4.4 mg of forskolin. In some embodiments: a) the
nutritional supplement further includes one or any combination of components
selected from the group consisting of about 180 mg to about 880 mg of acetyl-L-
carnitine per daily dosage of the nutritional supplement, about 112.5 mg to
about 550
mg of L-phenylalanine per daily dosage of the nutritional supplement, about
2.25 mg
to about 11 mg of vitamin B6 per daily dosage of the nutritional supplement,
and
about 10 mg to about 20 mg of piperine per daily dosage of the nutritional
supplement; b) in embodiments containing acetyl-L-carnitine, the ratio of
acetyl-L-
carnitine to forskolin can be about 200:1 by weight; c) particular embodiments
of the
nutritional supplement can include about 180 mg to about 880 mg of acetyl-L-
carnitine per daily dosage of the nutritional supplement; about 112.5 mg to
about 550
mg of L-phenylalanine per daily dosage of the nutritional supplement; about
2.25 mg
to about 11 mg of vitamin B6 per daily dosage of the nutritional supplement;
or d)
any combination of a) ¨ c). In a particular embodiment, the nutritional
supplement
comprises, per daily dosage: about 900 mg of artichoke extract standardized to
5%
cynarin; about 4 mg of forskolin; about 750 mg of acetyl-L-carnitine; about
500 mg
of L-phenylalanine; and about 5 mg vitamin B6.
[0010] In a further aspect, a method of increasing cognitive functioning in a
human
or other mammalian subject in need thereof is provided. The method includes
administering to the subject a nutritional supplement that includes
therapeutically
effective amounts of a phosphodiesterase 4 (PDE4) inhibiting flavonoid and a
cyclic
adenosine monophosphate (cAMP) increasing labdane diterpene. In some
embodiments: a) the flavonoid can be luteolin, a glycoside thereof, or a
physiologically acceptable salt thereof; b) the nutritional supplement can
include
artichoke extract as a source of the flavonoid; c) the labdane diterpene can
be
CA 02925318 2016-03-23
WO 2015/048590 PCT/US2014/057923
forskolin, a glycoside thereof, or a physiologically acceptable salt thereof;
d) the
nutritional supplement can further include therapeutically effective amounts
of one or
any combination of components selected from the group consisting of L-
phenylalanine, L-carnitine, acetyl-L-carnitine, vitamin B6, and piperine, and
a
physiologically acceptable salt thereof; or e) any combination of a) ¨ d).
[0011] In some embodiments, the method includes administering to the subject a
nutritional supplement that includes in daily dosage form about 202.5 mg to
about 990
mg of artichoke extract standardized to 5% cynarin, and about 0.9 mg to about
4.4 mg
of forskolin. In some embodiments: a) the nutritional supplement further
includes
one or any combination of components selected from the group consisting of
about
180 mg to about 880 mg of acetyl-L-carnitine per daily dosage of the
nutritional
supplement, about 112.5 mg to about 550 mg of L-phenylalanine per daily dosage
of
the nutritional supplement, about 2.25 mg to about 11 mg of vitamin B6 per
daily
dosage of the nutritional supplement, and about 10 mg to about 20 mg of
piperine per
daily dosage of the nutritional supplement; b) in embodiments containing
acetyl-L-
carnitine, the ratio of acetyl-L-carnitine to forskolin can be about 200:1 by
weight; c)
particular embodiments of the nutritional supplement can include about 180 mg
to
about 880 mg of acetyl-L-carnitine per daily dosage of the nutritional
supplement;
about 112.5 mg to about 550 mg of L-phenylalanine per daily dosage of the
nutritional
supplement; and about 2.25 mg to about 11 mg of vitamin B6 per daily dosage of
the
nutritional supplement; or d) any combination of a) ¨ c). In a particular
embodiment,
the nutritional supplement comprises, per daily dosage: about 900 mg of
artichoke
extract standardized to 5% cynarin; about 4 mg of forskolin; about 750 mg of
acetyl-
L-carnitine; about 500 mg of L-phenylalanine; and about 5 mg vitamin B6.
[0012] In a further aspect, a nutritional supplement for increasing
cognitive
functioning in a human, or other mammal, is provided. The nutritional
supplement
includes an effective amount of means for inhibiting phosphodiesterase 4
(PDE4), an
effective amount of means for increasing cyclic adenosine monophosphate
(cAMP),
and an effective amount of means for increasing acetylcholine. In some
embodiments,
the nutritional supplement also includes effective amounts of one or any
combination
CA 02925318 2016-03-23
WO 2015/048590 PCT/US2014/057923
of components selected from the group consisting of L-phenylalanine, L-
carnitine,
vitamin B6, and piperine.
[0013] In another aspect, a method of increasing cognitive functioning in a
human
or other mammalian subject in need thereof is provided. The method includes
administering to the subject a nutritional supplement that includes
therapeutically
effective amounts of means for inhibiting phosphodiesterase 4 (PDE4), means
for
increasing cyclic adenosine monophosphate (cAMP), and means for increasing
acetylcholine. In some embodiments, the nutritional supplement also includes
effective amounts of one or any combination of components selected from the
group
consisting of L-phenylalanine, L-carnitine, vitamin B6, and piperine.
[0014] In another aspect, a nutritional supplement for increasing cognitive
functioning in a human, or other mammal, is provided. The nutritional
supplement
includes effective amounts of mesembrenone, a glycoside thereof, or a
physiologically
acceptable salt thereof, and a cyclic adenosine monophosphate (cAMP)
increasing
labdane diterpene is provided. In some embodiments: a) the labdane diterpene
can
be forskolin, a glycoside thereof, or a physiologically acceptable salt
thereof; b) the
nutritional supplement can further include effective amounts of one or any
combination of components selected from the group consisting of L-
phenylalanine, L-
carnitine, acetyl-L-carnitine, vitamin B6, and piperine, and a physiologically
acceptable salt thereof; or c) any combination of a) ¨ b).
BRIEF DESCRIPTION OF THE DRAWINGS
[0015] For a more complete understanding of the present invention, reference
is
now made to the following descriptions taken in conjunction with the
accompanying
drawings, in which:
[0016] Figure 1 is a panel showing the chemical structures of various
compounds;
and
[0017] Figure 2 is a diagram showing suggested interactions of components of a
nutritional supplement.
6
DETAILED DESCRIPTION
[0019] In one aspect, a nootropic combination for increasing cognitive
functioning
is provided, comprising effective amounts of a phosphodiesterase 4 (PDE4)
inhibitor
and a cyclic adenosine monophosphate (cAMP) increasing agent. PDE4 inhibitors
and cAMP increasing agents can be natural or synthetic. Examples of PDE4
inhibitors include, but are not limited to, theophylline,
isobutylmethylxanthine,
rolipram, and benzamide derivatives of rolipram. PDE4 inhibitors found in
plant
extracts include, but are not limited to, PDE4 inhibiting flavonoids,
alkaloids, and
stilbenoids. Phosphodiesterase 4 is a member of a family of phosphodiesterase
enzymes that degrade 3',5'-cyclic nucleotides including cAMP. In humans,
phosphodiesterase 4 is abundant in brain tissue.
[0020] A flavonoid is a plant compound having a three ring backbone structure,
including flavonoid glycosides. Luteolin, shown in Fig. 1A, is a flavonoid
that can
inhibit 3',5'-cyclic nucleotide phosphodiesterase enzymes, including PDE4.
Luteolin
is found in certain plants such as artichoke (Cynara scolymus), and artichoke
extracts
containing luteolin are commercially available. An artichoke extract can be
standardized based upon the amount of cynarin, a caffeoylquinic acid present
in
artichoke. Other examples of PDE4 inhibiting flavonoids include, but are not
limited
to, quercetin (Fig. 1B) found in many plants including onion (Allium cepa),
hesperidin
(Fig. 1C) found in citrus plants, biochanin A (Fig. 1D) found in many plants
including
red clover (Trifoleum pretense), and genistein (Fig. 1E) found in soy beans.
Extracts
containing these plant compounds are commercially available. A non-limiting
example of a PDE4 inhibiting alkaloid is mesembrenone shown in Fig. 1F.
Mesembrenone is found in the succulent herb Sceletium tortuosum, also known as
7
CA 2925318 2020-04-06
CA 02925318 2016-03-23
WO 2015/048590 PCT/US2014/057923
kanna, and kanna extracts containing mesembrenone are commercially available.
Stilbenoids are stilbene derivatives having a C6-C2-C6 structure. A non-
limiting
example of a PDE4 inhibiting stilbenoid is resveratrol (Fig. 1G) found in
grapes and
other fruits. Grape extracts containing resveratrol are commercially
available.
Glycosides of luteolin, quercetin, hesperidin, biochanin A, genistein,
mesembrenone,
and resveratrol may also act as PDE4 inhibitors (references 46-51). PDE
inhibitors
are commercially available as purified components, for example, from Sigma-
Aldrich
Corp., St. Louis, Missouri, USA, and/or as plant extracts from, for example,
Now
Foods, Bloomingdale, Illinois, USA, Jarrow Formulas, Los Angeles, California,
USA,
Source Naturals, Scotts Valley, California, USA, Neutraceutical, Park City,
Utah,
USA, Swanson Health Products, Fargo, North Dakota, USA, Planetary Herbals,
Soquel, California, USA, and Better Body Sports, Ventura, California, USA.
[0021] Agents that increase intracellular cAMP levels include, but are not
limited
to, hormones and other bioactive agents such as dopamine, isoproterenol,
adenosine,
carbacyclin, endothelin, epinephrine, glucagon, parathyroid hormone,
prostaglandin,
vasopressin, cholera toxin, pertussis toxin, and cAMP increasing labdane
diterpenes.
A labdane diterpene is a natural product having a bicyclic diterpene backbone
structure. Forskolin, shown in Fig. 1H, is a labdane diterpene that can
stimulate the
enzyme adenylyl cyclase, which catalyzes the conversion of ATP to cAMP.
Forskolin
is found in the plant Coleus forskohlii, and Coleus forskohlii extracts
containing
forskolin are commercially available. Purified forskolin preparations are also
commercially available. Synthetic and natural derivatives of forskolin,
including but
not limited to forskolin glycosides, 7-deacetylforskolin and 6-
aminoacylforskolins,
can stimulate adenylyl cyclase activity. In some embodiments, forskolin in the
amount of about 1 to about 4 mg per daily dosage, or an amount of a forskolin
derivative or other cAMP increasing agent producing an effect on cognitive
functioning equivalent to about 1 to about 4 mg of forskolin per daily dosage,
is
included in the nootropic combination.
[0022] In some embodiments, the PDE4 inhibitor, the cAMP increasing agent, or
both, can be added to the nootropic combination in the form of one or more
plant
8
CA 02925318 2016-03-23
WO 2015/048590
PCT/US2014/057923
extracts. For example, a nootropic combination can contain artichoke extract
as a
source of the PDE4 inhibitor luteolin and Coleus forskohlii extract as the
source of
forskolin. Plant extracts that can be used as sources of PDE4 inhibitors
include, but
are not limited to, onion, citrus, red clover and soy bean, or any combination
thereof,
as described above.
[0023] Cyclic AMP appears to play a role in long term potentiation and other
nervous system processes. Combining an adenylyl cyclase stimulator with a PDE4
inhibitor can lead to enhanced cAMP production with decreased cAMP
degradation,
resulting in increased levels of cAMP in the body and increased intracellular
cAMP
levels. Thus, embodiments of the nootropic combination, including nutritional
supplements, can affect nervous system functioning when administered to a
subject.
[0024] In some
embodiments, the nootropic combination includes physiologically
acceptable or pharmaceutically acceptable salts of a PDE4 inhibitor, a cAMP
increasing agent, and/or other components of the combination. Physiologically
acceptable salts and pharmaceutically acceptable salts are well known in the
art and
include salts prepared from pharmaceutically acceptable non-toxic acids,
including
inorganic acids and organic acids. Suitable non-toxic acids can include
inorganic and
organic acids such as acetic, benzenesulfonic, benzoic, camphorsulfonic,
citric,
ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric,
isethionic,
lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic,
pantothenic,
phosphoric, succinic, sulfuric, tartaric acid, p-toluenesulfonic,
hydrochloric,
hydrobromic, phosphoric, sulfuric acids, and the like. Salts formed with, for
example,
a free carboxy group of an amino acid, can be derived from inorganic bases
including,
but not limited to, sodium, potassium, ammonium, calcium or ferric hydroxides,
and
organic bases including, but not limited to, isopropylamine, trimethylamine,
histidine,
and procaine.
[0025] The nootropic combination, or any individual components of the
nootropic
combination, can be taken orally in the form of a capsule, pill or tablet, for
example,
and can contain pharmaceutically or physiologically acceptable carriers. For
example,
9
CA 02925318 2016-03-23
WO 2015/048590 PCT/US2014/057923
inert, pharmaceutically or physiologically acceptable solid carriers can be
one or more
substances which may also act as diluents, flavoring agents, colorizers,
solubilizers,
lubricants, suspending agents, or binders. The solid carrier material can also
include
encapsulating material. Examples of carriers include, but are not limited to.
inert
diluents, such as calcium carbonate, sodium carbonate, sodium citrate,
lactose,
calcium phosphate, sodium phosphate, microcrystalline cellulose, corn starch,
potato
starch, and cellulose esters such as cellulose acetate, ethyl cellulose;
granulating and
disintegrating agents, for example, corn starch, or alginic acid, or complex
silicates;
binding agents, for example starch, polyvinylpyrrolidone, PEG-8000, gelatin or
gum
acacia, and lubricating agents, for example magnesium stearate, stearic acid,
sodium
lauryl sulfate, or talc.
[0026] Although oral administration of the nootropic combination or any of
its
components is the preferred route of administration, other means of
administration
such as intravenous, nasal or rectal administration, or by injection or
inhalation, are
also contemplated. Depending on the intended mode of administration, the
combination or any of its components may be in the form of solid, semi-solid
or liquid
dosage forms, such as, for example, liquids, suspensions, suppositories, or
powders.
In some embodiments, the nootropic combination can be administered in unit
dosage
form suitable for single administration of a precise dosage. One skilled in
this art may
further formulate the composition or any of its components in an appropriate
manner,
and in accordance with accepted practices, such as those disclosed in
Remington's
Pharmaceutical Sciences, Gennaro, Ed., Mack Publishing Co., Easton, Pa. 1990.
[0027] The effective amount of the nootropic combination and any of its
components can vary according to, for example, the weight of the subject
administered to, the mode of administration, and the general health of the
subject.
The dose or effective amount will be ascertainable by one skilled in the art
using
known techniques (for example, see Ansel, et al., Pharmaceutical Dosage Forms
and
Drug Delivery; Lieberman (1992) Pharmaceutical Dosage Forms (vols. 1-3),
Dekker,
ISBN 0824770846, 082476918X, 0824712692, 0824716981; and Lloyd (1999) The
Art, Science and Technology of Pharmaceutical Compounding).
CA 02925318 2016-03-23
WO 2015/048590 PCT/US2014/057923
[0028] In some embodiments, the nootropic combination can be administered
simultaneously or sequentially and in any order. For example, the PDE4
inhibitor, the
cAMP increasing agent, and other components of the combination can be
administered as a combination simultaneously or sequentially in any order,
depending
on the embodiment.
[0029] The nootropic combination can be in a form to be administered as a
single
preparation, such as a capsule or tablet, and can be in a daily dosage form.
In some
embodiments, the combination is a nutritional supplement.
[0030] The nootropic combination can be administered to a subject to increase
or
enhance cognitive functioning. Cognitive functioning refers to higher-order
brain
processes such as concentration, alertness, focus, attention, motivation,
wakefulness,
and long-term memory. An effective amount, or a therapeutically effective
amount,
of a substance is an amount that increases or enhances cognitive functioning
in the
subject.
[0031] In some cases, cognitive functioning can be assessed using cognitive
tests
such as long-term recall of studied material, spatial search and grammatical
reasoning
tests.
[0032] The subject can be a human or other mammal.
[0033] The primary means by which PDE4 inhibitors are theorized to improve
learning and memory is by lengthening the duration during which the secondary
messenger cyclic-adenosine monophosphate (cAMP) is present in cells, where it
can
activate the cAMP response element binding protein CREB and thus increase CREB
'S
gene transcription activities in the nucleus and mitochondria. These gene
transcription
activities are what are theorized to lead to long term potentiation (LTP)
activity which
is crucial to learning and memory. Additionally, increased transcription of
brain-
derived neurotrophic factor (BDNF) by CREB has been linked to improved short-
term
memory in studies (references 14-20).
11
CA 02925318 2016-03-23
WO 2015/048590
PCT/US2014/057923
[0034] Forskolin is a chemical derived from the plant Coleus forskohlii which
has
been widely used in traditional Ayurvedic medicine. It has also has been
extensively
studied due to its ability to increase levels of intracellular cAMP
(references 21-23).
[0035] Luteolin can inhibit the family of phosphodiesterase enzymes (PDE 1
through 5) that degrade 3',5'-cyclic nucleotides. Inhibition of
phosphodiesterase 1
and phosphodiesterase 5 have both shown beneficial activity with regard to
synaptic
plasticity (references 24-27). PDE 4 specific inhibitors are also known, such
as
rolipram (reference 28).
[0036] CREB's
activities in the cell have been shown to increase the transcription
of enzymes which are key enzymes in dopamine metabolism, such as tyrosine
hydroxylase. Increased transcription of these enzymes leads to increased
processing
of dopamine precursors. The essential amino acid L-phenylalanine is converted
into
L-tyrosine by phenylalanine hydroxylase and then converted into L-dopa by
tyrosine
hydroxylase. Vitamin B6 can support the conversion of L-dopa to dopamine by
dopa
decarboxylase (references 29-32). Thus, L-phenylalanine and/or Vitamin B6 can
be
added to embodiments of the nutritional supplement.
[0037] Some embodiments of the nootropic combination may lead to afternoon
sleepiness and a temporary decrease in short term memory. Studies have
provided
evidence that forskolin increases transcription of the enzyme
acetylcholinesterase.
Acetylcholinesterase breaks down acetylcholine in the brain. Sleepiness is a
common
symptom of medicines that are anti-cholinergic so it would follow that excess
acetylcholinesterase could lead to lower acetylcholine levels and thus
sleepiness.
Acetyl-L-carnitine has been shown to increase the levels of acetylcholine in
the brain
and thus could be helpful in counteracting increased transcription of
acetylcholinesterase by forskolin (references 33-35). Thus, acetyl-L-
carnitine, or L-
carnitine, can be added to the nutritional supplement. In embodiments
containing
acetyl-L-camitine or L-camitine, afternoon drowsiness and short-term memory
issues
can be largely mitigated.
12
CA 02925318 2016-03-23
WO 2015/048590 PCT/US2014/057923
[0038] Kanna extract and mesembrenone have been shown to significantly inhibit
PDE4 (reference 38). Embodiments containing kanna extract were effective at
increasing cognitive functioning, although less beneficial than artichoke
extract.
[0039] In particular embodiments, multiple components are combined to create a
synergistic combination for improving synaptic and cognitive functions in the
mammalian brain. These components include: a cyclic adenosine monophosphate
(cAMP) increasing labdane diterpene such as forskolin; a PDE4 inhibiting
flavonoid
such as Luteolin contained within artichoke extract; the amino acid L-
phenylalanine;
vitamin B6; and the quaternary ammonium compound L-carnitine or its acylated
derivative acetyl-L-camitine.
[0040] Although not wishing to be bound by theory, it is believed that when
these
components are taken together orally in the form of a nutritional supplement,
PDE-4 is
inhibited and cAMP is increased leading to sustained activation of CREB (cAMP
response element binding protein), which helps to maintain effective long-term
potentiation (LTP) and thus memory. In addition, L-phenylalanine is believed
to
provide adequate precursors to the dopaminergic metabolic pathway to
accommodate
upregulation of tyrosine hydroxylase by PDE4 inhibition, and vitamin B6 is
believed
to behave as a dopamine metabolic co-factor (see Fig. 2). Also, L-carnitine
and
acetyl-L-camitine are believed to counteract the upregulation of
acetylcholinesterase
caused by forskolin. Thus, it is believed that the dopamine co-factors provide
a steady
supply of co-factors to the enhanced D1/PKA/DARPP-32 signaling cascade caused
by
PDE-4 inhibition and the subsequent increase in dopamine synthesis and
turnover due
to increases in tyrosine hydroxylase gene transcription (references 36-45).
[0041] Some particular embodiments for an adult human that have been
determined
through experimentation include:
200 mg acetyl-L-carnitine;
1 mg forskolin;
225 mg artichoke extract standardized to 5% cynarin;
125 mg L-phenylalanine; and
13
CA 02925318 2016-03-23
WO 2015/048590 PCT/US2014/057923
2.5 mg vitamin B6.
[0042] Alternative formulas include:
200 mg acetyl-L-carnitine
1 mg forskolin
225 mg artichoke extract standardized to 5% cynarin;
or
1 mg forskolin
225 mg artichoke extract standardized to 5% cynarin
125 mg L-phenylalanine
[0043] These particular embodiments are exemplary and the weight of each
ingredient may be varied by 10% without significant degradation of efficacy.
Also,
from 1 to 2,1 to 3,1 to 4,2 to 3,2 to 4, 3 to 4, or 1, 2, 3 or 4 doses may be
taken per
day. Thus, in some embodiments, the range of ingredients per daily dosage can
be:
about 202.5 mg to about 495 mg, about 202.5 mg to about 742.5 mg, or
about 202.5 mg to about 990 mg artichoke extract standardized to 5% cynarin;
and
about 0.9 mg to about 2.2 mg, about 0.9 mg to about 3.3 mg, or about 0.9
mg to about 4.4 mg forskolin.
[0044] Alternatively, the daily dosage can be about 225 mg, about 450 mg,
about
675 mg or about 900 mg artichoke extract standardized to 5% cynarin; and about
1
mg, about 2 mg, about 3 mg, or about 4 mg forskolin, or can be varied by 10 %
of
such amounts.
[0045] Further, in some embodiments, the nutritional supplement can include
one or
a combination of the following ingredients, in ranges per daily dosage:
about 180 mg to about 440 mg, about 180 mg to about 660 mg, or about 180
mg to about 880 mg acetyl-L-carnitine;
about 112.5 mg to about 275 mg, about 112.5 mg to about 412.5 mg, or
about 112.5 mg to about 550 mg L-phenylalanine; and
14
CA 02925318 2016-03-23
WO 2015/048590 PCT/US2014/057923
about 2.25 mg to about 5.5 mg, about 2.25 mg to about 8.25 mg, or about
2.25 mg to about 11 mg vitamin B6.
[0046] Alternatively, the daily dosage can be about 200 mg, about 400 mg,
about
600 mg, or about 800 mg acetyl-L-carnitine; about 125 mg, about 250 mg, about
375
mg, or about 500 mg L-phenylalanine; and about 2.5 mg, about 5 mg, about 7.5
mg,
or about 10 mg vitamin B6, or can be varied by 10 % of such amounts.
[0047] The alkaloid piperine (Fig. 11) can also be included as a component
of the
nootropic combination, including the nutritional supplement. Piperine is
present in
black pepper and has been used in nutritional products to enhance the
bioavailability
of flavonoids by blocking glucuronidation in the liver and digestive tract.
Piperine has
been found to enhance the bioavailability of curcumin by 2000%, and enhance
the
bioavailability of resveratrol (references 52-53). In embodiments of the
nutritional
supplement, piperine can be included in the range of about 10 mg to about 20
mg per
daily dose of the nootropic combination.
[0048] Additional inactive ingredients such as different types of color,
filler, binder,
capsule, and coating are permissible.
[0049] In embodiments containing acetyl-L-camitine, a ratio of acetyl-L-
carnitine
to forskolin of about 200:1 by weight appears to provide particularly good
effects on
cognitive functioning.
[0050] Forskolin in the amount of 1-4 mg per daily dosage is less than the
amount
typically provided in forskolin supplements (25 mg to 50 mg). The 1-4 mg daily
dosage was found by the inventor to provide positive cognitive benefits, while
larger
amounts produced side effects and diminished or eliminated cognitive benefits.
[0051] As used herein, the term "about" in reference to an amount of a
substance
indicates an amount within experimental error.
CA 02925318 2016-03-23
WO 2015/048590 PCT/US2014/057923
[0052] It is to be understood that the ranges and limits mentioned herein
include all
sub-ranges located within the prescribed limits, inclusive of the limits
themselves
unless otherwise stated.
[0053] The present invention may be better understood by referring to the
accompanying examples, which are intended for illustration purposes only and
should
not in any sense be construed as limiting the scope of the invention.
EXAMPLE 1
Artichoke extract and forskolin
[0054] The inventor ingested 900mg artichoke extract standardized to 5%
cynarin
(Now Foods, Bloomingdale, Illinois) and 385 mg Coleus forskhohlii root
standardized
to 1% forskolin yielding 3.85 mg forskolin (Neutraceutical, Park City, Utah).
The
combination was administered once per morning. After taking the combination,
the
inventor performed better on spatial search and grammatical reasoning tests
compared
to baseline. The inventor felt increased motivation and could study for longer
periods
of time. He also had subjectively better recall of material that was studied.
The
inventor experienced excessive tiredness in the afternoon, and short term
memory, as
measured by a paired-associate-learning test "Paired Associates" (Cambridge
Brain
Sciences, Ontario, Canada) in which a pair of items is learned (an object and
its
location), was slightly negatively affected.
EXAMPLE 2
Artichoke extract, forskolin and L-phenylalanine
[0055] The inventor ingested artichoke extract and forskolin as in Example
1, and
also ingested up to 1500 mg L-Phenylalanine (Now Foods, Bloomingdale,
Illinois).
The combination was administered once per morning. After taking the
combination,
the inventor performed better on spatial search and grammatical reasoning
tests
compared to baseline, felt increased motivation, could study for longer
periods of
time, and had subjectively better recall of material that was studied.
Compared to the
16
CA 02925318 2016-03-23
WO 2015/048590
PCT/US2014/057923
combination containing just artichoke extract and forskolin, the inventor
experienced
less tiredness in the afternoon. Short term memory, as measured by the paired-
associate-learning test "Paired Associates" (Cambridge Brain Sciences,
Ontario,
Canada), was slightly negatively affected.
EXAMPLE 3
Artichoke extract, forskolin, L-phenylalanine and vitamin B6
[0056] The inventor ingested artichoke extract, forskolin and L-
phenylalanine as in
Example 2, and also ingested 5 mg vitamin B6 as part of a B vitamin complex
(Neutraceutical, Park City, Utah). The combination was administered once per
morning. After taking the combination, the inventor performed better on
spatial
search and grammatical reasoning tests compared to baseline, felt increased
motivation, could study for longer periods of time, and had subjectively
better recall
of material that was studied. The inventor experienced less tiredness in the
afternoon
and the effects of the stack did not diminish over several days of taking it.
Short term
memory, as measured by the paired-associate-learning test "Paired Associates"
(Cambridge Brain Sciences, Ontario, Canada), was slightly negatively affected.
EXAMPLE 4
Artichoke extract, forskolin, L-phenylalanine, vitamin B6 and acetyl-L-
carnitine
[0057] The inventor ingested artichoke extract, forskolin, L-phenylalanine
and
vitamin B6 as in Example 3, and also ingested 750 mg of acetyl-L-carnitine
(Primaforce, Burlington, North Carolina). The combination was administered
once
per morning. After taking the combination, the inventor performed better on
spatial
search and grammatical reasoning tests compared to baseline, felt increased
motivation, could study for longer periods of time, and had subjectively
better recall
of material that was studied. The inventor experienced no tiredness in the
afternoon.
The amount of acetyl-L-carnitine relative to forskolin was increased until the
inventor's paired associates scores no longer fell after taking the
combination.
17
CA 02925318 2016-03-23
WO 2015/048590 PCT/US2014/057923
EXAMPLE 5
[0058] This example is based on a testimonial by a subject. The subject was a
female with concentration and memory problems. The nutritional supplement was
in
capsular form, with a capsule including 300 mg artichoke extract standardized
to 5%
cynarin, ¨ 4/3 mg forskolin, 167 mg L-phenylalanine, 5/3 mg vitamin B6, and
250
mg acetyl-L-carnitine. Also included were cellulose, vegetable stearate and
silica as
carriers. After taking the nutritional supplement, the subject reported
increased focus,
energy and memory.
EXAMPLE 6
[0059] This example is based on a testimonial by a male subject. The
nutritional
supplement was in capsular form, with a capsule including 300 mg artichoke
extract
standardized to 5% cynarin, ¨ 4/3 mg forskolin, 167 mg L-phenylalanine, 5/3 mg
vitamin B6, and 250 mg acetyl-L-carnitine. Also included were cellulose,
vegetable
stearate and silica as carriers. After taking the nutritional supplement, the
subject
reported increased focus and mental vision.
EXAMPLE 7
[0060] This example is based on a testimonial by a male subject. The
nutritional
supplement was in capsular form, with a capsule including 300 mg artichoke
extract
standardized to 5% cynarin, ¨ 4/3 mg forskolin, 167 mg L-phenylalanine, 5/3 mg
vitamin B6, and 250 mg acetyl-L-carnitine. Also included were cellulose,
vegetable
stearate and silica as carriers. After taking the nutritional supplement, the
subject
reported increased focus and concentration.
EXAMPLE 8
[0061] The inventor ingested 25 mg kanna extract (Zembrint, Organic African
Red
Tea Imports, Los Angeles, California), 1500 mg L-phenylalanine, and 4 mg
forskolin
(Better Body Sports LLC, Ventura, California). This combination was
administered
18
once per morning. After taking the combination, the inventor obtained much
better
scores on "Polygons" and "Odd One Out" tests (Cambridge Brain Sciences,
Ontario,
Canada). Studying was much easier and more enjoyable.
References
[0062]
1. Rutten K, Van donkelaar EL, Ferrington L, et al. Phosphodiesterase
inhibitors
enhance object memory independent of cerebral blood flow and glucose
utilization in
rats. Neuropsychopharmacology. 2009;34(8):1914-25. PMID 19262466.
2. Egawa T, Mishima K, Matsumoto Y, Iwasaki K, Iwasaki K, Fujiwara M. Rolipram
and its optical isomers, phosphodiesterase 4 inhibitors, attenuated the
scopolamine-
induced impairments of learning and memory in rats. Jpn J Pharmacol.
1997;75(3):275-81. PMID 9434259.
3. Zhang HT, O'donnell JM. Effects of rolipram on scopolamine-induced
impairment
of working and reference memory in the radial-arm maze tests in rats.
Psychopharmacology (Berl). 2000;150(3):311-6. PMID 10923759.
4. Zhang HT, Crissman AM, Dorairaj NR, Chandler LJ, O'donnell JM. Inhibition
of
cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with
NMDA receptor antagonism. Neuropsychopharmacology. 2000;23(2):198-204. PMID
10882846.
5. Zhang HT, Huang Y, Suvarna NU, et al. Effects of the novel PDE4 inhibitors
MEM1018 and MEM1091 on memory in the radial-arm maze and inhibitory
avoidance tests in rats. Psychopharmacology (Berl). 2005;179(3):613-9. PMID
15672274.
6. Mclean JH, Smith A, Rogers S, Clarke K, Darby-king A, Harley CW. A
phosphodiesterase inhibitor, cilomilast, enhances cAMP activity to restore
conditioned
19
Date Recue/Date Received 2020-07-06
CA 02925318 2016-03-23
WO 2015/048590
PCT/US2014/057923
odor preference memory after serotonergic depletion in the neonate rat.
Neurobiol
Learn Mem. 2009;92(0:63-9. PMID 19233302.
7. Wang C, Yang XM, Zhuo YY, et al. The phosphodiesterase-4 inhibitor rolipram
reverses AP-induced cognitive impairment and neuroinflammatory and apoptotic
responses in rats. Int J Neuropsychopharmacol. 2012;15(6):749-66. PMID
21733236.
8. Rose GM, Hopper A, De vivo M, Tehim A. Phosphodiesterase inhibitors for
cognitive enhancement. Curr Pharm Des. 2005;11(26):3329-34. PMID 16250839.
9. Drott J, Desire L, Drouin D, Pando M, Haun F. Etazolate improves
performance in
a foraging and homing task in aged rats. Eur J Pharmacol. 2010;634(1-3):95-
100.
PMID 20223232.
10. Li LX, Cheng YF, Lin HB, Wang C, Xu JP, Zhang HT. Prevention of cerebral
ischemia-induced memory deficits by inhibition of phosphodiesterase-4 in rats.
Metab
Brain Dis. 2011;26(1):37-47. PMID 21327879.
11. Gallant M, Aspiotis R, Day S. et al. Discovery of MK-0952, a selective
PDE4
inhibitor for the treatment of long-term memory loss and mild cognitive
impairment.
Bioorg Med Chem Lett. 2010;20(22):6387-93. PMID 20933411.
12. Heaslip RJ, Evans DY. Emetic, central nervous system, and pulmonary
activities
of rolipram in the dog. Eur J Pharmacol. 1995;286(3):281-90. PMID 8608790.
13. Bruno 0, Fedele E, Prickaerts J, et al. GEBR-7b, a novel PDE4D selective
inhibitor that improves memory in rodents at non-emetic doses. Br J Pharmacol.
2011;164(8):2054-63. PMID 21649644.
14. Mackenzie SJ, Houslay MD. Action of rolipram on specific PDE4 cAMP
phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-
binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937
monocytic cells. Biochem J. 2000;347(Pt 2):571-8. 10749688.
CA 02925318 2016-03-23
WO 2015/048590 PCT/US2014/057923
15. Xu W, Kasper LH, Lerach S, Jeevan T, Brindle PK. Individual CREB-target
genes dictate usage of distinct cAMP-responsive coactivation mechanisms. EMBO
J.
2007;26(12):2890-903. PMID 17525731.
16. Benito E, Valor LM, Jimenez-minchan M, Huber W, Barco A. cAMP response
element-binding protein is a primary hub of activity-driven neuronal gene
expression.
J Neurosci. 2011;31(50):18237-50. PMID 22171029.
17. Lee J, Kim CH, Simon DK, et al. Mitochondrial cyclic AMP response element-
binding protein (CREB) mediates mitochondrial gene expression and neuronal
survival. J Biol Chem. 2005;280(49):40398-401. PMID 16207717.
18. Deisseroth K, Bito H, Tsien RW. Signaling from synapse to nucleus:
postsynaptic
CREB phosphorylation during multiple forms of hippocampal synaptic plasticity.
Neuron. 1996;16(1):89-101. PMID 8562094.
19. Kida S. A Functional Role for CREB as a Positive Regulator of Memory
Formation and LTP. Exp Neurobiol. 2012;21(4):136-40. PMID 23319873.
20. Suzuki A, Fukushima H, Mukawa T, et al. Upregulation of CREB-mediated
transcription enhances both short- and long-term memory. J Neurosci.
2011;31(24):8786-802. PMID 21677163.
21. Ammon HP, Muller AB. Forskolin: from an ayurvedic remedy to a modern
agent.
Planta Med. 1985;51(6):473-7. PMID 17345261.
22. Seamon KB, Daly JVV. Forskolin: a unique diterpene activator of cyclic AMP-
generating systems. J Cyclic Nucleotide Res. 1981;7(4):201-24. PMID 6278005.
23. Barad M, Bourtchouladze R, Winder DG, Golan H, Kandel E. Rolipram, a type
IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-
lasting
long-term potentiation and improves memory. Proc Natl Acad Sci USA.
1998;95(25):15020-5. PMID 9844008.
21
CA 02925318 2016-03-23
WO 2015/048590 PCT/US2014/057923
24. Brown JE, Rice-evans CA. Luteolin-rich artichoke extract protects low
density
lipoprotein from oxidation in vitro. Free Radic Res. 1998;29(3):247-55. PMID
9802556.
25. Yu MC, Chen JH, Lai CY, Han CY, Ko WC. Luteolin, a non-selective
competitive inhibitor of phosphodiesterases 1-5, displaced [31-1]-rolipram
from high-
affinity rolipram binding sites and reversed xylazine/ketamine-induced
anesthesia. Eur
J Pharmacol. 2010;627(1-3):269-75. PMID 19853596.
26. Kitagawa Y, Hirano T, Kawaguchi SY. Prediction and validation of a
mechanism
to control the threshold for inhibitory synaptic plasticity. Mol Syst Biol.
2009;5:280.
PMID 19536203.
27. Puzzo D, Sapienza S, Arancio 0, Palmeri A. Role of phosphodiesterase 5 in
synaptic plasticity and memory. Neuropsychiatr Dis Treat. 2008;4(2):371-87.
PMID
18728748.
28. Otmakhov N, Khibnik L, Otmakhova N, et al. Forskolin-induced LTP in the
CA1
hippocampal region is NMDA receptor dependent. J Neurophysiol. 2004;91(5):1955-
62. PMID 14702333.
29. Piech-dumas KM, Tank AW. CREB mediates the cAMP-responsiveness of the
tyrosine hydroxylase gene: use of an antisense RNA strategy to produce CREB-
deficient PC12 cell lines. Brain Res Mol Brain Res. 1999;70(2):219-30. PMID
10407170.
30. Kumer SC, Vrana KE. Intricate regulation of tyrosine hydroxylase activity
and
gene expression. J Neurochem. 1996;67(2):443-62. PMID 8764568.
31. Slominski A, Zmijewski MA, Pawelek J. L-tyrosine and L-
dihydroxyphenylalanine as hormone-like regulators of melanocyte functions.
Pigment
Cell Melanoma Res. 2012;25(1):14-27. PMID 21834848.
22
CA 02925318 2016-03-23
WO 2015/048590
PCT/US2014/057923
32. Amadasi A, Bertoldi M, Contestabile R, et al. Pyridoxal 5'-phosphate
enzymes as
targets for therapeutic agents. Curr Med Chem. 2007;14(12):1291-324. PMID
17504214.
33. Curtin BF, Pal N, Gordon RK, Nambiar MP. Forskolin, an inducer of cAMP, up-
regulates acetylcholinesterase expression and protects against organophosphate
exposure in neuro 2A cells. Mol Cell Biochem. 2006;290(1-2):23-32. PMID
16924422.
34. Hartvig P, Lindstrom B, Pettersson E, Wiklund L. Reversal of postoperative
somnolence using a two-rate infusion of physostigmine. Acta Anaesthesiol
Scand.
1989;33(8):681-5 PMID 2589000.
35. White HL, Scates PW. Acetyl-L-carnitine as a precursor of acetylcholine.
Neurochem Res. 1990;15(6):597-601. PMID 2215852.
36. Alasbahi RH, Melzig MF.(2012) "Forskolin and derivatives as tools for
studying
the role of CAMP." Pharmazie. 2012 Jan;67(1):5-13. PMID: 22393824.
37. Yu MC, Chen JH, Lai CY, Han CY, Ko WC.(2010) "Luteolin, a non-selective
competitive inhibitor of phosphodiesterases 1-5,displaced [3E11-rolipram from
high-
affinity rolipram binding sites and reversed xylazine/ketamine-induced
anesthesia."
Eur JPharmacol. 2010 Feb10;627(1-3):269-75. doi: 10.1016/j.ejphar.2009.10.031.
Epub 2009 Oct 22 PMID: 19853596.
38. Harvey AL , Young LC, Viljoen AM, Gericke NP.(2011) "Pharmacological
actions of the South African medicinal and functional food plant Sceletium
tortuosum
and its principal alkaloids." J Ethnopharmacol. 2011 Oct 11;137(3) :1124 9.
doi
:10.1016/j.jep.2011.07.035. Epub 2011 Jul 20. PMID: 21798331.
39. Dwight E. Matthews (2008) "An Overview of Phenylalanine and Tyrosine
Kinetics in Humans" J Nutr. Author manuscript; available in PMC 2008 March 17.
Published in final edited form as: J Nutr. 2007 June; 137(6 Suppi 1):15495-
1575S.PMCID: PMC2268015.
23
CA 02925318 2016-03-23
WO 2015/048590 PCT/US2014/057923
40. Lichtstein HC, Gunsalus IC, Umbreit WW (1945). "Function of the vitamin B6
group; pyridoxal phosphate (codecarboxylase) in transamination" (PDF). J Bioi
Chem.
161 (1): 311- 20.PMID 21005738.
41. Rani PJ , Panneerselvam C.(2001 )."Protective efficacy of L-carnitine on
acetylcholinesterase activity in aged rat brain." J Gerontal A Bioi Sci Med
Sci. 2001
Mar;56(3):B140-1.PMID: 11253151.
42. Villa RF, Ferrari F, Gorini A.(2013) "ATP-ases of synaptic plasma
membranes in
striatum: Enzymatic systems for synapses functionality by in vivo
administration of 1-
acetylcarnitine in relation to Parkinson's Disease." Neuroscience. 2013 Jun
25;248C:414-426. doi: 10.1016/j.neuroscience.2013.06.027. [Epub ahead of
print]
PMID: 23806723.
43. Curtin BF, Pal N, Gordon RK, Nambiar MP. (2006). "Forskolin, an inducer of
cAMP, upregulates acetylcholinesterase expression and protects against
organophosphate exposure in neuro 2A cells" Mol Cell Biochem. 2006 Oct;290(1-
2):23-32. Epub 2006 Aug 19. PMID 16924422.
44. Gong B , Vitolo OV, Trinchese F, Liu S, Shelanski M, Arancio 0., (2004)
"Persistent improvement in synaptic and cognitive functions in an Alzheimer
mouse
model after rolipram treatment." J Clin Invest. 2004 Dec;114(11):1624-34.
PMID:
15578094.
45. Voisin P, Bernard M. (2013) "Cyclic AMP-dependent regulation of tyrosine
hydroxylase mRNA and immunofluorescence levels in rat retinal precursor
cells."
Cell Tissue Res. 2013 May;352(2):207-16. doi: 10.1007/s00441-013-1555-4. Epub
2013 Jan 26. PMID: 2335501.
46. Chan AL, Huang HL, Chien HC, Chen CM, Lin CN, Ko WC. Inhibitory effects
of quercetin derivatives on phosphodiesterase isozymes and high-affinity [(3)
H]-
rolipram binding in guinea pig tissues. Invest New Drugs. 2008;26(5):417-24.
PMID
18264679.
24
CA 02925318 2016-03-23
WO 2015/048590
PCT/US2014/057923
47. Yang YL, Hsu HT, Wang KH, Wang CS, Chen CM, Ko WC. Hesperidin-3'-o-
methylether is more potent than hesperidin in phosphodiesterase inhibition and
suppression of ovalbumin-induced airway hyperresponsiveness. Evid Based
Complement Alternat Med. 2012;2012:908562. PMID 23082087.
48. Park SJ, Ahmad F, Philp A, et al. Resveratrol ameliorates aging-related
metabolic
phenotypes by inhibiting cAMP phosphodiesterases. Cell. 2012;148(3):421-33.
PMID
22304913.
49. Ko WC, Lin LH, Shen HY, Lai CY, Chen CM, Shih CH. Biochanin a, a
phytoestrogenic isoflavone with selective inhibition of phosphodiesterase 4,
suppresses ovalbumin-induced airway hyperresponsiveness. Evid Based Complement
Alternat Med. 2011;2011:635058. PMID 21437195.
50. Nichols MR, Morimoto BH. Tyrosine kinase-independent inhibition of cyclic-
AMP phosphodiesterase by genistein and tyrphostin 51. Arch Biochem Biophys.
1999;366(2):224-30. PMID 10356287.
51. Harvey AL, Young LC, Viljoen AM, Gericke NP. Pharmacological actions of
the
South African medicinal and functional food plant Sceletium tortuosum and its
principal alkaloids. J Ethnopharmacol. 2011;137(3):1124-9. PMID 21798331.
52. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of
piperine on the pharmacokinetics of curcumin in animals and human volunteers.
Planta Med. 1998;64(4):353-6. PMID 9619120.
53. Johnson JJ, Nihal M, Siddiqui 1A, et al. Enhancing the bioavailability of
resveratrol by combining it with piperine. Mol Nutr Food Res. 2011;55(8):1169-
76.
PMID 21714124.
[0063] Although the present invention has been described in connection with
the
preferred embodiments, it is to be understood that modifications and
variations may
be utilized without departing from the principles and scope of the invention,
as those
CA 02925318 2016-03-23
WO 2015/048590
PCT/US2014/057923
skilled in the art will readily understand. Accordingly, such modifications
may be
practiced within the scope of the invention and the following claims.
26
